Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1239 studies found for:    "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
21 Completed PI-88 in Hepatocellular Carcinoma After Hepatectomy
Condition: Carcinoma, Hepatocellular
Intervention: Drug: PI-88
22 Completed Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Refametinib (BAY86-9766)
23 Completed
Has Results
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin;   Drug: Doxorubicin/Placebo
24 Completed Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Capecitabine in HCC
25 Recruiting Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton radiotherapy;   Procedure: Radiofrequency Ablation
26 Not yet recruiting Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Tenofovir disoproxil fumarate
27 Recruiting c-Met Second-Line Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: MSC2156119J
28 Active, not recruiting Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Mapatumumab;   Drug: Placebo;   Drug: Sorafenib
29 Recruiting Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: IGRT;   Drug: Capecitabine;   Drug: Oxaliplatin
30 Active, not recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
31 Completed East-West Hepatocellular Carcinoma Study Group
Condition: Carcinoma, Hepatocellular
Intervention:
32 Not yet recruiting A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: ABC294640
33 Terminated A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Device: Amplitude-modulated electromagnetic fields
34 Completed
Has Results
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
35 Completed Oxaliplatin in Unresectable Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Oxaliplatin
36 Completed Testing of ADI-PEG in Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: ADI-PEG 20
37 Completed A National Registry of Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention:
38 Recruiting A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299;   Drug: Sorafenib
39 Terminated Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Procedure: percutaneous ablation of hepatocellular carcinoma
40 Active, not recruiting Dose Escalation Study for Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Radiation: Stereotactic Body Radiation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.